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Letter to the Editor re ‘‘Four Essential Drugs
Needed for Quality Care of the Dying:
A Delphi-Study Based International Expert Consensus Opinion’’
Katherine Clark, MBBS, MMed, FRACP,1 Caitlin Sheehan, BMed, FRACP, FAChPM,2
and David C. Currow, MPH, FRACP2
Dear Editor:
The authorship team of the article ‘‘Four essential drugs
needed for quality care of the dying: A Delphi-study based
international expert consensus opinion’’1 are to be congratu-
lated for undertaking work that aims to provide guidance in
care of the actively dying, an area hindered by a lack of robust
research. Whilst systematically documenting opinions of
palliative medicine specialists who care for the dying, the
article’s conclusion that this will help improve the quality of
care requires consideration.
The article recommends four classes of medications be
readily available to dying people with the aim of enabling
optimal management of common problems experienced by
dying people: pain, dyspnea, nausea, anxiety, respiratory
tract secretions, and agitation at the end of life. Recommended
medications include opioids, preferably morphine; benzodi-
azepines, preferably midazolam; an antipsychotic, preferably
haloperidol; and a glycopyrronium or hyoscine formulation.
High-quality patient care can be defined as an approach
that minimizes harm whilst aligning with people’s expecta-
tions.2 Dying people and their relatives have articulated that
they expect health care providers to manage physical and
psychological symptoms well, with expectations even higher
when such care is delivered by specialist services.3 Despite
excellent intentions, palliative care clinicians and researchers
have done little to improve systematically the evidence base
for prescribing when people are actually dying. Few data exist
to inform clinicians’ understanding of how people’s actual
experiences align with their articulated wishes.4 Symptoms
are managed based on relatives’ and staff’s assumptions of
the experience of the dying person, with a ‘‘good death’’ often
being seen as quiet and calm. Achieving this often requires
sedation, for which the dying person will very rarely have
given consent. This requires consideration, especially when
evidence suggests people facing death will forgo symptom
control to remain as alert and interactive for as long as pos-
sible.3 We ignore patients’ wishes at our peril if we are to be
truly patient centered.
Of the symptoms listed above, only palliation of pain and
breathlessness are supported by robust evidence. The rec-
ommendation that antimuscarinic agents are required to
manage respiratory secretions1 is not supported by the small
number of placebo controlled observations, which suggest, at
best, no benefit. Administering compounds that cross the
blood-brain barrier places people at risk of adverse effects
including agitation and delirium, so if a medication is to be
used it should be glycopyrrolate or hyoscine butylbromide.5
The recommendation that there is a need for a benzodiazepine
is also questioned. The choice of midazolam requires mostly
parenteral administration in the absence of pharmacokinetic
data for the other routes by which it is administered. In con-
trast, alternative benzodiazepines such as lorazepam and
clonazepam can be simply administered via the sublingual
route with well-defined pharmacokinetics. Principles for the
choice of medications have been described in the palliative
care literature,6 and in the 21st century we should be relying
less and less on injectable medications in the last hours and
days of life as other evidence-based routes of administration
become available.
Improving the quality of care for the dying requires the
most sophisticated and nuanced research that can possibly be
designed. There is a real need for research to provide an evi-
dence base from which to manage distressing symptoms
when they occur. This must include defining the optimal
approach to objectively measuring symptom burdens and
managing those symptoms with the same attention paid to
minimizing harm that occurs at any other point in a person’s
life. Only then can quality of care for the dying be assured.
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